Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE-MSS-1
2024-517745-14-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of bms-986368 in multiple sclerosis (MS) (4 arms), sponsored by Celgene Corporation. Primary endpoint: Change from baseline to Week 6 in TNmAS-MALL. Planned start Sep 2025; status: authorised.
02
Drugs
bms-986368
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-517745-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517745-14-00.